Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
enGene Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology issuer focused on non-viral genetic medicines. The company’s SEC reports cover Nasdaq-listed common shares and warrants, emerging growth company status, clinical disclosures for detalimogene voraplasmid and the LEGEND trial, and material agreements tied to financing and operating arrangements.
Recent filings include Form 8-K reports on clinical and financial updates, amendments to a loan and security agreement, an at-the-market sales agreement under a shelf registration statement, executive compensation arrangements, and the completed corporate name change from enGene Holdings Inc. Proxy materials cover annual meeting matters, audited financial statements, director elections, auditor appointment, governance proposals, and shareholder voting procedures.
enGene Therapeutics Inc. reports that Interim Chief Business Officer Chinoporos Constantine holds a stock option covering 75,000 common shares. The option has an exercise price of $1.7500 per share, expires on 2036-06-16, and vests monthly in substantially equal amounts over 48 months commencing June 16, 2026, subject to continued service.
Kathleen P. Richton, SVP, Finance and Treasurer of enGene Therapeutics Inc., reports initial beneficial ownership of equity awards. Her holdings include 6,900 unvested RSUs granted January 30, 2026, vesting annually over four years from January 15, 2027, plus stock options for 45,000, 13,900 and 105,000 common shares at exercise prices of $7.39, $9.53 and $1.75, expiring between 2035 and 2036, all vesting over multi‑year schedules subject to continued service.
enGene Therapeutics Inc. has a significant shareholder group associated with Acorn Bioventures reporting beneficial ownership of its common shares. Anders Hove, through his control of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, reports beneficial ownership of 3,357,282 common shares, representing 5.0% of enGene’s common stock.
Acorn Bioventures, L.P. reports beneficial ownership of 1,410,059 shares (2.1%), while Acorn Bioventures 2, L.P. reports 1,947,223 shares (2.9%). Each Acorn general partner entity reports the same respective share amounts with shared voting and dispositive power, and no sole voting or dispositive power. Percentages are based on 66,989,466 common shares outstanding as of June 9, 2026.
enGene Therapeutics Inc. provides an update on detalimogene voraplasmid, an investigational non‑viral gene therapy for high‑risk non‑muscle invasive bladder cancer (NMIBC). In the Phase 2 LEGEND pivotal Cohort 1 in BCG‑unresponsive NMIBC with carcinoma in situ, 125 patients were enrolled. Interim data as of 21 April 2026 show a 54% complete response at any time, with a 43.0% 6‑month complete response rate based on landmark and Kaplan‑Meier analyses.
The safety profile in this cohort shows 55.2% of participants experienced at least one treatment‑related adverse event, mostly grade 1–2, with 4.8% having grade ≥3 events, low dose interruptions and discontinuations (each 2.4%), and a median 8‑day resolution time. The company highlights plans to evaluate a polidocanol surfactant bladder rinse to potentially increase efficacy and durability while preserving ease of use, and notes $285M in cash is expected to support operations through planned BLA filing and potential approval, alongside an NMIBC market forecast of over $20B and a future total addressable patient population of more than 120,000.
enGene Therapeutics Inc. reported that longtime chairman and director Dr. Richard Glickman resigned from the board, effective July 15, 2026, and that existing director Michael Heffernan has been appointed chairman. The company states that Dr. Glickman’s resignation was not due to any disagreement regarding operations, policies, or practices.
The company highlights upcoming regulatory milestones for its lead program, detalimogene voraplasmid, a non-viral gene therapy in the Phase 2 LEGEND trial for high-risk non-muscle invasive bladder cancer. The pivotal Cohort 1 includes 125 patients with BCG-unresponsive disease and is intended to support a planned Biologics License Application, with a pre-BLA FDA meeting and initiation of BLA submission planned for the second half of 2026 and a potential FDA approval in 2027. Detalimogene has received RMAT and Fast Track designations and is included in the FDA’s CMC Development and Readiness Pilot program.
enGene Therapeutics Inc. filed an amended report updating details of its previously announced strategic restructuring, which includes reducing its workforce by about 50% to streamline operations and preserve cash. The company now expects restructuring cash costs of approximately $5.7–$6.4 million and non-cash stock-based compensation of about $4.7–$5.0 million, mainly from accelerated option vesting.
enGene also estimates up to $1.7 million in cash retention costs and up to $2.8 million in non-cash stock-based compensation tied to new performance-based equity retention awards. These awards, including a 400,000-share option grant to CEO Ronald Cooper at $1.75 per share, vest only if FDA milestones for detalimogene are met by late 2027 and 2028.
enGene Therapeutics Inc. director Philip Astley-Sparke received a grant of stock options to acquire 31,000 common shares. The options have an exercise price of $1.75 per share and now represent a total option holding of 31,000 shares.
The option vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. The options are scheduled to expire on June 16, 2036, if not exercised earlier.
enGene Therapeutics Inc. director Gerald A. Brunk received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and were awarded at no cost.
The options expire on June 16, 2036. According to the disclosure, the option vests fully on the earlier of the first anniversary of the June 9, 2026 vesting commencement date or the company’s 2027 annual meeting of shareholders. Following this grant, Brunk holds options for 31,000 shares directly.
enGene Therapeutics Inc. director Richard M. Glickman received a grant of stock options covering 31,000 common shares. The options have an exercise price of $1.75 per share and expire on June 16, 2036. Following this grant, he holds 31,000 options directly.
The option award vests fully on the earlier of the first anniversary of the vesting commencement date, which was June 9, 2026, or the company’s 2027 annual meeting of shareholders. This is a compensation-related award rather than an open-market purchase or sale.
enGene Therapeutics Inc. director and Interim Chief Medical Officer William Grossman reported receiving two stock option awards. He was granted options covering 200,000 common shares at an exercise price of $1.75 per share, vesting fully on the earlier of the first anniversary of a June 9, 2026 vesting commencement date or the company’s 2027 annual shareholder meeting, for his service as a non-executive director.
He was also granted options on 31,000 common shares at an exercise price of $1.75 per share, vesting in substantially equal monthly installments over 12 months, subject to his continued service as Interim Chief Medical Officer. Both awards expire on June 16, 2036 and are compensation grants rather than open-market purchases or sales.